In addition, the receipt of Jak inhibitor monotherapy was not associated with higher odds of hospitalization or death compared with TNF inhibitor monotherapy (OR, 0.60; 95% CI, 0.22-1.64; P = .32) among patients in the SECURE-IBD registry. Here, TNF is linked to inflammatory bowel disease.